BioCryst Pharmaceuticals stock gets a new science board
BioCryst Pharmaceuticals has appointed a seven-member Scientific Advisory Board to guide its rare-disease research and development strategy, formalizing a shift towards external innovation. The company reported strong Q2 2026 revenues of USD 218.25 million and raised its full-year revenue guidance. Analysts maintain a "Moderate Buy" consensus with an average 12-month price target significantly above its current Nasdaq closing price.
‘We’re here at the party now:’ AstraZeneca opens new Kendall hub with big hiring plans
AstraZeneca has opened a new 570,000-square-foot R&D center in Cambridge, Massachusetts, at 290 Binney Street. This 18-story facility is designed to accommodate approximately 2,000 employees, focusing on oncology and rare disease research. The opening signifies a significant expansion for the company in the Kendall Square area.
Exagen leaves S&P Global BMI Index: what it means for Exagen stock
Exagen Inc. has been removed from the S&P Global BMI Index, an event that could impact passive fund demand for its stock. This change comes as the company reports strong operating figures, including a 16% year-over-year revenue increase in Q2 2026 and raised full-year revenue guidance, driven by growth in its AVISE testing products for autoimmune conditions. Investors are now focused on whether Exagen can sustain its operational improvements in the latter half of the year.
Form 4 BELITE BIO, INC For: Oct 01 Filed by: Scholl Hendrik Peter
This Form 4 filing details insider transactions for BELITE BIO, INC (BLTE) by Chief Medical Officer Scholl Hendrik Peter. The report indicates multiple sales of American depositary shares on October 1, 2026, executed under a Rule 10b5-1 trading plan. These transactions involved a total of 500 shares at varying weighted average prices, leaving the reporting person with 14,500 shares beneficially owned indirectly through Bioptima Ltd.
Lightning Round: Avery Dennison is a winner, says Jim Cramer
Jim Cramer, host of "Mad Money," has identified Avery Dennison as a winning stock. He also shared his insights on other companies including Sarepta Therapeutics and Ciena Corp during his "Lightning Round" segment.
Argenx stock gets fresh VYVGART data before Q3 results
Argenx stock saw its price at USD 912.87 on October 5, 2026, driven by new VYVGART data expanding its clinical treatment scope across neuromuscular diseases. The company's Q2 revenue hit USD 1.54 billion, surpassing estimates, and it will release Q3 results on October 21, 2026, to assess sustained VYVGART demand. Analyst ratings show a strong positive outlook with an average 12-month price target of USD 1,158.61.
A Look at Zimmer Biomet Holdings Inc (ZBH) After 3.7% Gain -- GF Value $125.41 vs Price $91.57
Zimmer Biomet Holdings Inc (ZBH) saw its shares rise by 3.7% to $91.57, positioning it significantly below its GF Value™ of $125.41, suggesting a 27.0% undervaluation. The company boasts a strong GF Score™ of 81/100, driven by high rankings in valuation, momentum, and profitability, although its financial strength is moderate. Despite insider sales totaling $1.6 million, 17 gurus hold ZBH shares, with a mix of additions and trimmings, indicating cautious optimism among institutional investors.
Exagen stock gains 3.55 percent as Q2 growth nears breakeven
Exagen (XGN) stock rose 3.55% as its Q2 2026 revenue of $19.94 million exceeded estimates, marking a 16% year-over-year increase. The company narrowed its adjusted EBITDA loss and raised its full-year revenue guidance to $72 million to $75 million, with plans to reach adjusted EBITDA breakeven at $80 million in annual revenue. Analysts maintain a "Moderate Buy" consensus with an average 12-month target price 13.8% above the current trading price.
Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results
Xenetic Biosciences, Inc. reported its third-quarter 2025 financial results, highlighting continued progress in its immuno-oncology programs and strategic collaborations. The company is advancing its systemic DNase I program towards Phase 1 clinical development for difficult-to-treat cancers and secured approximately $3.9 million in net proceeds from an October 2025 offering to extend its cash runway and fund preclinical and exploratory studies. Financially, Xenetic reported a net loss of $0.5 million, increased R&D and G&A expenses, and increased royalty revenue, ending the quarter with $4.1 million in cash.
Cigna Group stock after-hours at EUR 242.80: plus 1.55 percent versus prior close
Cigna Group's stock closed after-hours at EUR 242.80, a 1.55 percent increase from its prior close of EUR 239.10 at Lang & Schwarz. This price was recorded at 10:17 p.m. CEST on October 5, 2026. The company also reaffirmed its 2026 full-year financial guidance and announced a multiyear modernization initiative and future adjusted EPS growth targets.
AbbVie (ABBV) Flags $216M IPR&D Expense Impacting Q3 and Full-Ye
AbbVie announced a pre-tax charge of $216 million for acquired in-process research and development (IPR&D) and milestone payments, reducing Q3 and full-year EPS guidance. While the company maintains a strong GF Score and attractive dividend yield, concerns are raised about the dividend's sustainability due to an 85% payout ratio and the stock's modest overvaluation according to GF Value™. Insider selling and a weaker financial strength rating also suggest a cautious outlook for investors.
Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 13th
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Aardvark Therapeutics, Inc. (NASDAQ:AARD) for alleged misleading statements regarding its IPO and securities between February 13, 2025, and May 14, 2026. Investors who purchased Aardvark stock during this period are encouraged to contact the firm to discuss their legal rights and apply for lead plaintiff status before October 13, 2026. The lawsuit claims that Aardvark overstated the safety and prospects of its product ARD-101, leading to investor damages.
PepsiCo Recalls Gatorade In 37 States Over Undeclared Dyes
PepsiCo has issued a recall for 122,021 cases of Gatorade across 37 U.S. states due to undeclared artificial food colorings, Yellow No. 5 and/or Yellow No. 6. The recall, classified as Class II by the FDA, involves 28-ounce bottles of Lemon Lime, Lemon Lime Zero, Orange, and Orange Zero flavors with expiration dates from April through June 2027. Consumers are advised to check their products, though PepsiCo has not yet announced refund eligibility.
American Well CFO Mark Hirschhorn sells $55,666 AMWL stock By Investing.com
American Well CFO Mark Hirschhorn sold 4,282 shares of AMWL stock for $55,666 on October 1, 2026, to cover tax liabilities from restricted stock unit vesting. This "sell to cover" transaction was not a discretionary trade. Despite a recent slight dip, AMWL shares have seen a significant 101% gain over the past year and are considered undervalued by InvestingPro, with the company recently surpassing earnings and revenue expectations.
Avantor stock heads toward October 28 results as estimates hold
Avantor (AVTR) stock was trading at USD 15.77 on October 5, 2026, ahead of its Q3 2026 earnings report scheduled for October 28. Analysts have a consensus "Hold" rating with an average price target of USD 12.47, significantly below the current trading price. The company's Q2 revenue beat expectations, but the market will be focusing on profitability and guidance in the upcoming report given a year-over-year decline in adjusted EBITDA.
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
AbbVie and Genmab announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial, showing that epcoritamab combined with R-CHOP significantly improved progression-free survival in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients. The trial demonstrated a 51% reduction in the risk of disease progression or death, suggesting epcoritamab plus R-CHOP could become a new standard of care. This marks the first Phase 3 study of a bispecific antibody combination to achieve such a result in this patient population, prompting the companies to engage global regulatory authorities for next steps.
Form 4 Cencora, Inc. For: Oct 01 Filed by: SANCHEZ ROBERT E
This Form 4 filing indicates that Robert E. Sanchez, a director at Cencora, Inc. (COR), acquired 275 shares of common stock on October 1, 2026. These shares were received as a grant of restricted stock units that will vest 100% on the first anniversary of the grant date. The filing also notes that Sanchez beneficially owns 197 shares through a revocable trust.
AbbVie (ABBV) Flags $216M Q3 Charge Impacting Earnings Amid Dividend Focus
AbbVie Inc. (ABBV) announced a $216 million pre-tax charge for Q3 2026, stemming from acquired in-process research and development and milestone expenses, which will reduce diluted EPS by about $0.11. Despite an attractive 2.55% dividend yield and consistent 5.2% growth, the company's high 85% payout ratio and modest overvaluation suggest caution. The GF Score of 77 reflects strong profitability but highlights weaker financial strength and ongoing insider selling.
McKesson stock gains 2.06 percent as CVS pact extends to 2032
McKesson stock rose 2.06% on October 5, 2026, driven by the planned extension of its pharmaceutical distribution agreement with CVS Health through June 2032. The company reaffirmed its fiscal 2027 adjusted EPS guidance and long-term growth target. Despite the stock trading below its yearly high, analysts maintain a "Moderate Buy" consensus, with an average target price 5.71% above the current trading price.
Danaher Corporation stock reports 5.5 percent revenue growth for Q2 2026
Danaher Corporation reported strong second-quarter 2026 results with revenue of USD 6.26 billion, exceeding expectations, and EPS of USD 1.94, beating the consensus estimate of USD 1.85. Revenue grew 5.5 percent year over year, and analysts like RBC Capital have raised price targets, with a Moderate Buy consensus. The company expects adjusted diluted 2026 EPS of USD 8.45 to USD 8.60 and anticipates reporting third-quarter results on October 21, 2026.
What Is Drawing Fresh Attention To BridgeBio Pharma (BBIO)?
BridgeBio Pharma (BBIO) is gaining investor attention due to recent positive clinical trial data for BBP-418 and acoramidis, despite a recent dip in share price. While one valuation narrative suggests the company is 169% overvalued, another DCF model indicates it trades significantly below fair value. This discrepancy highlights differing views on the company's future commercial success and clinical/regulatory risks.
Biogen's Chief Accounting Officer Sean Godbout Reports October 2026 Stock Transactions via Form 4
Biogen's Chief Accounting Officer Sean Godbout filed a Form 4 detailing his October 2026 equity transactions. These included the grant of 985 restricted stock units, the conversion of 27 RSUs into common stock, and the sale of 8 shares to cover tax withholdings. Following these transactions, Godbout directly held 1,458.9845 shares of Biogen common stock.
DaVita stock after-hours at EUR 158.78: plus 0.19 percent versus prior close
DaVita Inc. stock traded after-hours at EUR 158.78 on October 5, 2026, marking a 0.19 percent increase from its prior close. The company also highlighted initiatives from its 2025 Community Care Report, including the DaVita Ladders program and Bridge to Your Dreams program for nursing students, along with significant investment in tuition reimbursement.
STERIS stock after-hours at EUR 189.30: plus 2.16 percent versus prior close
STERIS stock traded at EUR 189.30 after-hours on October 5, 2026, marking a 2.16 percent increase from its prior close of EUR 185.30. This rise follows an announcement on September 29, 2026, that STERIS plc plans to invest $600 million in a new manufacturing and distribution center in North Carolina, creating 335 jobs.
William Blair initiates Revvity stock with outperform on AI tailwind By Investing.com
William Blair initiated coverage on Revvity Inc. (NYSE: RVTY) with an outperform rating, citing expected growth in life sciences markets and artificial intelligence opportunities. The firm projects strong organic growth and higher earnings per share than consensus estimates, driven by AI-enabled drug discovery and robust instruments portfolio. Despite the stock surging year-to-date and appearing overvalued by some analyses, Revvity's recent Q2 earnings surpassed expectations, further supported by AI-related demand.
Form 4 BIOGEN INC. For: Oct 01 Filed by: Godbout Sean
Sean Godbout, Chief Accounting Officer of Biogen Inc. (BIIB), filed a Form 4 detailing transactions on October 1st and 2nd, 2026. The filing indicates the acquisition of 27 shares of common stock through a derivative transaction and the disposal of 8 shares to cover taxes, resulting in a beneficial ownership of 1,458.9845 shares. Additionally, Godbout was granted 985 restricted stock units on October 1, 2026, vesting in three equal annual installments.
Form 4 Zai Lab Ltd For: Oct 01 Filed by: Chen Yajing
This Form 4 filing indicates changes in beneficial ownership for Chen Yajing, Chief Financial Officer of Zai Lab Ltd. The filing details the acquisition of 920 American Depositary Shares (ADSs) upon vesting of Restricted Share Units (RSUs) and the disposal of 315 ADSs withheld to cover taxes, resulting in a total beneficial ownership of 36,240 direct ADSs. Each ADS represents ten ordinary shares of Zai Lab Ltd.
Cencora stock after-hours at EUR 280.35: plus 2.08 percent after the Xetra close
Cencora stock closed at EUR 280.35 after-hours on October 5, 2026, marking a 2.08 percent increase from its prior close. The company is scheduled to release its fiscal fourth-quarter results on November 4, 2026, and recently appointed Robert E. Sanchez as an independent director to its board, effective October 1, 2026.
To cover taxes, Alignment Healthcare (ALHC) CMO proposes selling 36,000 shares.
Alignment Healthcare's Chief Medical Officer, Hyong (Ken) Kim, M.D., has proposed selling 36,000 common shares of ALHC stock, valued at approximately $305,280. This transaction is categorized as a "sale-to-cover" for tax purposes, not a discretionary trade, and the final number of shares sold will depend on tax withholding rates and the stock price at the time of sale. The shares originated from the vesting of 85,034 restricted stock units in October 2023.
Form 144 Amylyx Pharmaceuticals For: 5 October By Investing.com
The article announces the filing of Form 144 by Amylyx Pharmaceuticals for October 5th, as reported by Investing.com. It is a brief announcement that does not provide further details about the filing but includes stock market data and other popular articles as peripheral content.
Genentech pens $1.27B deal to access Alector’s preclinical blood-brain barrier asset
Genentech has entered a deal worth up to $1.27 billion with Alector to acquire exclusive development and commercialization rights to Alector's preclinical asset, AL050. This asset utilizes Alector’s blood-brain barrier delivery platform to treat neurodegenerative diseases like Parkinson’s and Alzheimer’s. The partnership, which includes a $100 million upfront payment, provides Alector with a significant cash infusion, extending its runway and allowing it to advance other programs after previous clinical-stage setbacks.
At $2.32 a share, Alto Neuroscience (ANRO) CFO exercises options for 55,000 shares.
Alto Neuroscience's President and CFO, Nicholas Conrad Smith, exercised options for 55,000 common shares at $2.32 per share on October 2, 2026. This transaction increased his direct holdings to 79,060 common shares, while he still holds 57,405 options. The options had a vesting schedule that began in September 2022, with monthly installments thereafter, contingent on continuous service.
Abbott, Nevro Spinal Cord Stimulator Lawsuits Get Consolidated
Lawsuits against Abbott Laboratories and Nevro Corp. concerning allegedly defective spinal cord stimulator devices have been consolidated in federal courts. The US Judicial Panel on Multidistrict Litigation ordered the consolidation of over 25 lawsuits against Abbott in Illinois and more than 20 lawsuits against Nevro in California. Both companies will now face these combined legal challenges in their respective federal districts.
20,000 director stock options carry a $1.64 exercise price at CalciMedica (CALC).
CalciMedica director Allan Shaw was granted 20,000 director stock options on October 1, 2026, with an exercise price of $1.64 per share. These options will expire on September 30, 2036, and vest in monthly installments over one year starting August 19, 2026, or fully vest by the company's 2027 annual meeting. This information was disclosed in a Form 4 SEC filing.
Twist Bioscience TWST Rallies On AI Drug Discovery Push
Twist Bioscience (TWST) shares rallied by over 10% following a significant data and services deal with Eli Lilly's AI/ML TuneLab platform, positioning TWST as a key "picks-and-shovels" data supplier for AI drug discovery. Analysts from Leerink and Guggenheim have significantly raised their price targets, citing increased visibility into pharma adoption and conservative revenue guidance. Despite being a high-growth, loss-making company, improving cash burn and a clear path to adjusted EBITDA breakeven by Q4 FY26 are attracting traders.
Universal Health Services sets Q3FY26 earnings release for Oct 26
Universal Health Services announced it will release its Q3FY26 financial results after market close on Monday, October 26, 2026. A conference call for investors and analysts is scheduled for Tuesday, October 27, 2026, at 9:30 am ET, with registration required for telephone participation. The company, headquartered in King of Prussia, Pennsylvania, is a major provider of hospital and healthcare services, operating over 480 facilities across multiple regions.
Stryker stock after-hours at EUR 253.75: plus 3.61 percent versus prior close
Stryker stock traded at EUR 253.75 after-hours on October 5, 2026, marking a 3.61 percent increase from its prior close. The company also announced the launch of its Mako 4 SmartRobotics platform in India. This fourth-generation Mako system aims to enhance surgical planning and execution for various joint replacement procedures.
Align Technology hit as appeals court revives dental aligners antitrust claims
Align Technology (ALGN) faces renewed antitrust claims after a federal appeals court reversed a lower court's summary judgment. The company, known for Invisalign, is accused of monopolizing the clear dental aligner market and digital image scanners. This decision means Align will likely face claims from consumers and dental practices that it minimized competition.
Tactile Systems Technology stock gains after Q2 earnings beat
Tactile Systems Technology's stock rose after the company beat Q2 earnings estimates, reporting $0.34 EPS against a $0.14 consensus. Analysts maintain a "Moderate Buy" consensus with an average 12-month target of $38.40, significantly above the current trading price. The medical device company posted revenues of $85.70 million and a net income of $7.785 million for Q2 2026.
McKesson, CD&R near $5 billion-plus deal to buy Option Care, FT reports
US drug distributor McKesson and private equity firm Clayton Dubilier & Rice are reportedly close to acquiring infusion services provider Option Care Health for over $5 billion, including debt. This potential deal, which could be announced as early as Tuesday, would expand McKesson's healthcare services footprint, following its previous acquisition of Precision Medicine Group. Option Care's shares surged 21% on the news.
Welltower stock fell 1.56 percent as revenue grew 39.1 percent on October 5, 2026,
Welltower Inc. (WELL) stock fell 1.56% to USD 224.16 on October 5, 2026, despite a 39.1% year-over-year revenue increase to USD 3.54 billion for the second quarter. The company missed EPS estimates but exceeded revenue consensus, leading to a mixed financial picture. Analysts maintain a "Moderate Buy" consensus with an average price target of USD 255.91, and the company is set to release its third-quarter results on October 26, 2026.
Spyre Therapeutics launches public stock offering
Spyre Therapeutics Inc. has announced the commencement of an underwritten public offering of its common stock, with plans to grant underwriters an option to purchase additional shares. The biotechnology company intends to use the net proceeds to advance its gastroenterology, rheumatology, and dermatology programs, including funding for preclinical studies, clinical trials, and late-stage development of SPY072. The offering is contingent on market conditions, and its completion, size, and terms are not guaranteed.
McKesson, CD&R in talks for $5B deal for Option Care Health: FT
McKesson and private equity firm Clayton, Dubilier & Rice (CD&R) are reportedly nearing a $5 billion deal, including debt, to acquire medical infusion services provider Option Care Health. The proposed terms indicate CD&R would hold a 51% stake, with McKesson owning the remainder and retaining the right to eventually purchase CD&R's share. Following the news, Option Care Health's stock rose approximately 22% in after-hours trading.
Zimmer Biomet Americas President Gary Craig Campbell Files Initial SEC Ownership Disclosure
Gary Craig Campbell, President, Americas of Zimmer Biomet Holdings, Inc., filed an initial SEC ownership disclosure (Form 3) on October 5, 2026. The filing details his derivative securities holdings as of October 1, 2026, which include 8,515 Restricted Stock Units (RSUs) across five tranches and five fully vested employee stock options covering 12,053 shares. The report indicated no non-derivative security holdings.
Novavax Shorts on Edge as Russia Plague Fears Spread
Novavax (NVAX) shares jumped over 20% following news of a suspected plague death at a Siberian research institute, sparking fears reminiscent of the COVID-19 pandemic. The rally, also benefiting other vaccine stocks like Moderna (MRNA) and Emergent BioSolutions (EBS), appears to be driven by sentiment and short covering rather than scientific relevance, as plague is treatable with antibiotics while Novavax specializes in viral vaccines. The situation highlights a classic short squeeze setup for Novavax, with 30.43% of its float held by short sellers.
Did New Science Board Just Shift BioCryst's (BCRX) Investment Narrative?
BioCryst Pharmaceuticals recently formed a seven-member Scientific Advisory Board to guide its research and development, which could significantly impact its investment narrative by addressing execution risk and pipeline expansion beyond its current primary drug, ORLADEYO. While the board brings seasoned expertise in drug development and rare diseases, near-term reliance on ORLADEYO's commercial success and managing competition in hereditary angioedema remains crucial. Analysts project substantial revenue growth and a shift to profitability by 2029 for BioCryst, with the new board potentially influencing the clinical and regulatory strategies required to achieve these targets and reduce single-product risk.
343 shares withheld for taxes leave BridgeBio Oncology (BBOT) COO with 14,152 shares.
BridgeBio Oncology Therapeutics, Inc.'s COO & Principal Financial Officer, Idan Elmelech, had 343 shares of common stock withheld for tax obligations related to restricted stock unit vesting on October 1, 2026. The transaction was priced at $3.94 per share, and following this, Elmelech directly holds 14,152 shares of common stock. This action is a standard procedure for satisfying tax liabilities upon the vesting of equity awards.
BridgeBio Oncology COO Idan Elmelech Reports RSU Tax Withholding via Share Disposal
Idan Elmelech, COO and Principal Financial Officer of BridgeBio Oncology Therapeutics, Inc., reported a transaction on October 1, 2026, where 343 shares of common stock were withheld for tax purposes related to restricted stock units vesting. The shares were withheld at $3.94 each. Following this transaction, Elmelech directly owns 14,152 shares of Common Stock.
Spyre Therapeutics launches underwritten public offering of common stock
Spyre Therapeutics has initiated an underwritten public offering of its common stock to finance its immunology pipeline, focusing significantly on advancing SPY072 into late-stage development for hidradenitis suppurativa. The net proceeds are intended for preclinical studies, clinical trials, and manufacturing, with Jefferies, TD Cowen, Leerink Partners, and Stifel acting as joint book-running managers. The offering includes a 30-day option for underwriters to purchase an additional 15% of shares, providing flexibility for further capital if demand is high.
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
Spyre Therapeutics has announced a proposed underwritten public offering of common stock to secure funding for its ongoing development programs. The proceeds will primarily support advancing its Gastroenterology, Rheumatology, and Dermatology programs through clinical stages, including Phase 3 readiness, and initiating late-stage development for SPY072 in hidradenitis suppurativa. The offering's completion is contingent on market and other conditions.
